Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03180502
Other study ID # NRG-BN005
Secondary ID NCI-2017-00203NR
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date August 2, 2017
Est. completion date January 2030

Study information

Verified date March 2024
Source NRG Oncology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized phase II clinical trial studies the side effects and how well proton beam or intensity-modulated radiation therapy works in preserving brain function in patients with IDH mutant grade II or III glioma. Proton beam radiation therapy uses tiny charged particles to deliver radiation directly to the tumor and may cause less damage to normal tissue. Intensity-modulated or photon beam radiation therapy uses high-energy x-ray beams shaped to treat the tumor and may also cause less damage to normal tissue. Patients will be more likely to be randomized to proton beam radiation therapy. It is not yet known if proton beam radiation therapy is more effective than photon-based beam intensity-modulated radiation therapy in treating patients with glioma.


Description:

PRIMARY OBJECTIVES: I. To determine whether proton therapy, compared to intensity-modulated radiation therapy (IMRT), preserves cognitive outcomes over time as measured by the Clinical Trial Battery Composite (CTB COMP) score (calculated from the Hopkins Verbal Learning Test Revised [HVLT-R]) Total Recall, HVLT-R Delayed Recall, HVLT-R Delayed Recognition, Controlled Oral Word Association (COWA) test, Trail Making Test (TMT) part A and part B. SECONDARY OBJECTIVES: I. To assess whether treatment with proton therapy preserves neurocognitive function as measured separately by each test, HVLT-R, TMT parts A & B, and COWA. II. To document and compare treatment related symptoms, overall symptom impact, and disease related factor groupings, utilizing the M.D. Anderson Symptom Inventory Brain Tumor (MDASI-BT), for both treatment arms. III. To assess whether treatment with proton therapy, compared to IMRT, results in superior quality of life as measured by the Linear Analog Scale Assessment (LASA) scale. IV. To compare local control patterns of failure and overall and progression-free survival between the two treatment arms. V. To assess adverse events. TERTIARY OBJECTIVES: I. To assess the impact of chemotherapy use on cognitive outcomes, symptom outcomes and quality of life. II. To assess dose-response relationships between neuro-anatomic dosimetry and cognitive outcomes within and between treatment arms. III. To evaluate the association between tumor molecular status and cognition at baseline and within and between treatment arms over time. IV. To assess patterns of failure and pseudo progression as a function of radiation delivery type and dose received. V. To assess local control, overall survival and, progression free survival in IDH mutant grade II and III tumors. VI. To collect blood samples for future studies seeking to correlate changes in peripheral blood biomarkers (genes, micro ribonucleic acid [RNA], proteins, lymphocyte count, melatonin, etc) and the study endpoints. VII. To document and compare the impact of low to intermediate gliomas and therapy on patients' work and activity participation (The Work Productivity and Activity Impairment [WPAI:GH] Questionnaire: General Health version 2.0) as well as the relationship between changes in patients' work and activity participation and neurocognitive function and patient reported symptoms and interference. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients undergo photon-based IMRT once daily (QD), 5 days a week for 6 weeks for a total of 30 fractions. Beginning 4 weeks after completion of radiation therapy, patients receive standard of care temozolomide for 5 days. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression of unacceptable toxicity. ARM II: Patients undergo proton beam radiation therapy QD, 5 days a week for 6 weeks for a total of 30 fractions. Beginning 4 weeks after completion of radiation therapy, patients receive standard of care temozolomide for 5 days. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression of unacceptable toxicity. After completion of study treatment, patients are followed up at 6 and 12 months and then yearly for 10 years.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 148
Est. completion date January 2030
Est. primary completion date June 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Prior to STEP 1 REGISTRATION - Tumor tissue must be available for submission for central pathology review - Documentation from the enrolling site confirming the presence of IDH mutation and 1p/19q status; the provided information must document assays performed in clinical laboratory improvement amendments (CLIA)-approved laboratories - Only English speaking patients are eligible to participate as the cognitive and quality of life assessments are available only in English - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry - Karnofsky performance status of >= 70 within 30 days prior to registration - Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 - Platelets >= 100,000 cells/mm^3 - Hemoglobin >= 10.0 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10.0 g/dl is acceptable) - Bilirubin =< 1.5 upper limit of normal (ULN) - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN - BUN < 30 mg/dl - Serum creatinine < 1.5 mg/dl - Post-operative magnetic resonance (MR) imaging with contrast is mandatory obtained for radiation therapy planning; enrolling sites are highly encouraged to obtain thin-slice (<1.5 mm) 3D T1 pre and post contrast and Axial T2/FLAIR sequences for planning purposes - Prior to STEP 2 REGISTRATION - The following baseline neurocognitive assessments must be completed and uploaded prior to step 2 registration: HVLT-R, TMT Parts A and B, and COWA - Completion of all items on the following baseline quality of life forms: MDASI-BT, LASA QOL, WPAI-GH and Employment Questionnaire. These quality of life forms will be required and data entered at step 2 registration. - Financial clearance for proton therapy treatment prior to step 2 registration - Centrally reviewed histologically proven diagnosis of supratentorial, Word Health Organization (WHO) grade II or III astrocytoma, oligodendroglioma or oligoastrocytoma, with IDH mutation Exclusion Criteria: - Definitive clinical or radiologic evidence of metastatic disease; if applicable - Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years; (for example, carcinoma in situ of the breast, oral cavity or cervix are permissible) - Prior cranial radiotherapy or radiotherapy to the head and neck where potential field overlaps would exist - Prior chemotherapy or radiotherapy for any brain tumor - Histologic diagnosis of glioblastoma (WHO grade IV) or pilocytic astrocytoma (WHO grade I) - Definitive evidence of multifocal disease - Planned use of cytotoxic chemotherapy during radiation (only adjuvant temozolomide therapy will be used on this protocol) - Patients with infra-tentorial tumors are not eligible - Prior history of neurologic or psychiatric disease believed to impact cognitive function - The use of memantine during or following radiation is NOT allowed - Severe, active co-morbidity defined as follows: - Unstable angina or congestive heart failure requiring hospitalization within 6 months prior to enrollment - Transmural myocardial infarction within the last 6 months prior to step 2 registration; evidence of recent myocardial infarction or ischemia by the findings of S-T elevations of >= 2 mm using the analysis of an electrocardiogram (EKG) performed within 28 days prior to step 2 registration (Note: EKG to be performed only if clinical suspicion of cardiac issue) - New York Heart Association grade II or greater congestive heart failure requiring hospitalization within 12 months prior to step 2 registration - Serious and inadequately controlled arrhythmia at step 2 registration - Serious or non-healing wound, ulcer or bone fracture or history of abdominal fistula, intra-abdominal abscess requiring major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to step 2 registration, with the exception of the craniotomy for surgical resection - Acute bacterial or fungal infection requiring intravenous antibiotics at the time of step 2 registration - Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for coagulation parameters are not required for entry into this protocol - Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of step 2 registration - Human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter; acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that HIV testing is not required for entry into this protocol - Any other severe immunocompromised condition - Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity - End-stage renal disease (i.e., on dialysis or dialysis has been recommended) - Any other major medical illnesses or psychiatric treatments that in the investigator's opinion will prevent administration or completion of protocol therapy - Inability to undergo MRI with and without contrast (e.g. claustrophobia, non-MRI compatible implant or foreign body, gadolinium allergy or renal dysfunction preventing the patient from receiving gadolinium- institutional guidelines should be used to determine if patients are at risk for renal dysfunction); note that patients with severe claustrophobia are permitted on this study if they are willing and able to undergo MRI with adequate sedation or anesthesia

Study Design


Intervention

Radiation:
IMRT (Intensity-Modulated Radiation Therapy)
Undergo IMRT
Proton Beam Radiation Therapy
Undergo proton beam radiation therapy
Drug:
Temozolomide
Chemotherapy drug

Locations

Country Name City State
United States Emory Proton Therapy Center Atlanta Georgia
United States Emory University Hospital Midtown Atlanta Georgia
United States Emory University Hospital/Winship Cancer Institute Atlanta Georgia
United States Maryland Proton Treatment Center Baltimore Maryland
United States University of Maryland/Greenebaum Cancer Center Baltimore Maryland
United States UM Upper Chesapeake Medical Center Bel Air Maryland
United States University of Alabama at Birmingham Cancer Center Birmingham Alabama
United States Boca Raton Regional Hospital Boca Raton Florida
United States Massachusetts General Hospital Cancer Center Boston Massachusetts
United States Northwestern University Chicago Illinois
United States Case Western Reserve University Cleveland Ohio
United States Central Maryland Radiation Oncology in Howard County Columbia Maryland
United States Northwestern Medicine Cancer Center Delnor Geneva Illinois
United States UM Baltimore Washington Medical Center/Tate Cancer Center Glen Burnie Maryland
United States M D Anderson Cancer Center Houston Texas
United States University of Kansas Cancer Center Kansas City Kansas
United States University of Kansas Cancer Center - North Kansas City Missouri
United States University of Kansas Cancer Center - Lee's Summit Lee's Summit Missouri
United States Miami Cancer Institute Miami Florida
United States Laura and Isaac Perlmutter Cancer Center at NYU Langone New York New York
United States University of Kansas Cancer Center at North Kansas City Hospital North Kansas City Missouri
United States University of Oklahoma Health Sciences Center Oklahoma City Oklahoma
United States University of Kansas Cancer Center-Overland Park Overland Park Kansas
United States University Hospitals Parma Medical Center Parma Ohio
United States University of Pennsylvania/Abramson Cancer Center Philadelphia Pennsylvania
United States University Hospitals Portage Medical Center Ravenna Ohio
United States Mayo Clinic in Rochester Rochester Minnesota
United States Washington University School of Medicine Saint Louis Missouri
United States Maine Medical Center- Scarborough Campus Scarborough Maine
United States FHCC at Northwest Hospital Seattle Washington
United States University of Washington Medical Center - Montlake Seattle Washington
United States Mercy Hospital Springfield Springfield Missouri
United States Northwestern Medicine Cancer Center Warrenville Warrenville Illinois
United States University of Kansas Hospital-Westwood Cancer Center Westwood Kansas

Sponsors (2)

Lead Sponsor Collaborator
NRG Oncology National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Assessment of dose-response relationships The dose-response relationship between cognition, using the CTB COMP and each individual test score, and neuro-anatomic dosimetry, including the hippocampus and whole brain, will be assessed. The decline, as calculated using the Reliable Change Index, will be used to determine neurocognitive impairment. The dose-response curve will be modeled using a non-linear model. Up to 10 years
Other Assessment of tumor molecular status Cognition, using the CTB COMP and each individual test score, will be compared by 1p19q status. A general linear model using maximum likelihood estimation will be built for CTB COMP and each individual test score over time including baseline test score, 1p19q status, treatment arm, and stratification factors. Up to 10 years
Primary Change in cognition as measured by the CTB COMP score Assessed with a general linear model with maximum likelihood estimation. Three models will be conducted. Baseline CTB COMP score, treatment arm, time, treatment by time interaction (if significant) and stratification factors will be included in the model for the primary endpoint. A second model will be built with these same variables and relevant covariates, such as total volume of intracranial disease, gross tumor volume (GTV) and clinical tumor volume (CTV) size, histology, anti-epileptic use, and disease response to therapy (as measured by Response Assessment in Neuro-Oncology [RANO] criteria Baseline to up to 10 years
Secondary Change in quality of life as measured by the LASA scale The change from baseline to each follow-up time point (calculated as baseline score subtracted from follow-up score) will be compared between treatment arms using a t-test, or Wilcoxon test if the data is not normally distributed. A one-sided alpha=0.05 will be used for the LASA. A general linear model with maximum likelihood estimation will be used to assess symptom and QOL trends across time. Up to 10 years
Secondary Change in symptoms as measured by MDASI-BT The change from baseline to each follow-up time point (calculated as baseline score subtracted from follow-up score) will be compared between treatment arms using a t-test, or Wilcoxon test if the data is not normally distributed. A reduced one-sided significance level will be used for the multiple comparisons in the MDASI-BT using the Bonferroni adjustment (alpha=0.017 for disease related factors and alpha=0.025 for treatment related symptoms and overall impact). A general linear model with maximum likelihood estimation will be used to assess symptom trends across time. Baseline to up to 10 years
Secondary Cognition as measured by COWA The COWA will be analyzed using a general linear model with maximum likelihood estimation. Standardized scores will be used. Up to 10 years
Secondary Cognition as measured by TMT parts A and B The TMT parts A & B will be analyzed using a general linear model with maximum likelihood estimation. Standardized scores will be used. Up to 10 years
Secondary Cognition as measured by HVLT-R The HVLT-R will be analyzed using a general linear model with maximum likelihood estimation. Standardized scores will be used. Up to 10 years
Secondary Incidence of adverse events (AEs) graded according to the National Cancer Institute's Common Terminology for Adverse Events version 4.0 Counts of all AEs by grade will be provided by treatment arm. Counts and frequencies will be provided for the worst grade AE experienced by the patient by treatment arm. Grade 3+ treatment related AEs will be compared between arms using a chi-square test, or Fisher's exact test if cell frequencies are < 5, at the one-sided 0.05 significance level. Up to 10 years
Secondary Local control as assessed by RANO criteria Local control will be estimated using cumulative incidence, treating death prior to an event as a competing risk. Gray's test will be used to compare local control rates between arms. Cause-specific Cox proportional hazards models will be used for local control, adjusting for treatment arm and stratification factors. A two-sided significance level of 0.05 will be used for comparisons between arms. Up to 10 years
Secondary Overall survival (OS) OS will be estimated using the Kaplan-Meier method and compared between arms using the log rank test. Cox proportional hazards models will be used for OS adjusting for treatment arm and stratification factors. From randomization to the date of death, assessed up to 10 years
Secondary Progression-free survival (PFS) A confidence interval will be used to determine if the PFS rate in the proton arm is greater than that in the photon at 1 year. PFS will be estimated using the Kaplan-Meier method and compared between arms using the log rank test. Cox proportional hazards models will be used for PFS adjusting for treatment arm and stratification factors. From date of randomization to date of progression or death, whichever occurs first, assessed up to 10 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04539574 - An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors N/A
Enrolling by invitation NCT04461002 - Evaluation of the Correlation Between Molecular Phenotype and Radiological Signature (by PET-scanner and MRI) of Incident WHO II and III Grade Gliomas.
Terminated NCT01902771 - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors Phase 1
Completed NCT03242824 - The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma Phase 2
Recruiting NCT04186832 - Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy N/A
Completed NCT00424554 - Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed) Phase 2
Recruiting NCT05968053 - Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT02805179 - A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma Phase 2
Terminated NCT04556929 - Enhanced Detection in Glioma Excision N/A
Not yet recruiting NCT06408428 - Glioma Intraoperative MicroElectroCorticoGraphy N/A
Recruiting NCT06043232 - MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas
Not yet recruiting NCT06043765 - Reducing Cognitive Impairment in Glioma With Repetitive Transcranial Magnetic Stimulation and Cognitive Strategy Training N/A
Not yet recruiting NCT05025969 - Evaluation of the Incidence of NTRK Gene Fusion in Adult Brain Tumours
Completed NCT02978261 - Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas Phase 1
Terminated NCT01502605 - Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas Phase 1
Completed NCT01836536 - Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients N/A
Completed NCT01479686 - iMRI Guided Resection in Cerebral Glioma Surgery Phase 3
Completed NCT01212731 - Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
Withdrawn NCT00985036 - Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients N/A